Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight

被引：0
|
作者：
Ji Hye Min
Ho Yun Lee
Hoyeong Lim
Myung-Ju Ahn
Keunchil Park
Man Pyo Chung
Kyung Soo Lee
机构：
[1] Samsung Medical Center,Deparment of Radiology
[2] Sungkyunkwan University School of Medicine,The Division of Hematology
[3] Samsung Medical Center,Oncology, Department of Internal Medicine
[4] Sungkyunkwan University School of Medicine,Division of Respiratory and Critical Care Medicine at the Department of Internal Medicine
[5] Samsung Medical Center,undefined
[6] Sungkyunkwan University School of Medicine,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 68卷
关键词：
Tyrosine kinase inhibitors; Drug-associated interstitial lung disease; Pulmonary toxicity; Gefitinib; Erlotinib; Sorafenib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1099 / 1109
页数：10
相关论文
共 50 条
  • [31] New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer
    Doebele, Robert C.
    Oton, Ana B.
    Peled, Nir
    Camidge, D. Ross
    Bunn, Paul A., Jr.
    LUNG CANCER, 2010, 69 (01) : 1 - 12
  • [32] Is there a role for lung surgery in initially unresectable non-small cell lung cancer after tyrosine kinase inhibitor treatment?
    Nguk Chai Diong
    Chia-Chuan Liu
    Chih-Shiun Shih
    Mau-Ching Wu
    Chun-Jen Huang
    Chen-Fang Hung
    World Journal of Surgical Oncology, 20
  • [33] Is there a role for lung surgery in initially unresectable non-small cell lung cancer after tyrosine kinase inhibitor treatment?
    Diong, Nguk Chai
    Liu, Chia-Chuan
    Shih, Chih-Shiun
    Wu, Mau-Ching
    Huang, Chun-Jen
    Hung, Chen-Fang
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [34] Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
    Fujimoto, S.
    Tanaka, T.
    Katsurada, N.
    Hazama, D.
    Nagano, T.
    Yamamoto, M.
    Tachihara, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1683 - S1684
  • [35] Radiation therapy in patients with non-small cell lung cancer and interstitial lung abnormalities
    Ito, M.
    Katano, T.
    Okada, H.
    Sakuragi, A.
    Minami, Y.
    Abe, S.
    Adachi, S.
    Oshima, Y.
    Kubo, A.
    Fukui, T.
    Ito, S.
    Suzuki, K.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1073 - S1074
  • [36] Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease
    Sato, Yusuke
    Watanabe, Satoshi
    Ota, Takeshi
    Kushiro, Kohei
    Fujisaki, Toshiya
    Takahashi, Miho
    Ohtsubo, Aya
    Shoji, Satoshi
    Nozaki, Koichiro
    Ichikawa, Kosuke
    Hokari, Satoshi
    Kondo, Rie
    Hayashi, Masachika
    Ishikawa, Hiroyuki
    Miyabayashi, Takao
    Abe, Tetsuya
    Miura, Satoru
    Tanaka, Hiroshi
    Okajima, Masaaki
    Terada, Masaki
    Ishida, Takashi
    Iwashima, Akira
    Sato, Kazuhiro
    Yoshizawa, Hirohisa
    Aoki, Nobumasa
    Ohshima, Yasuyoshi
    Koya, Toshiyuki
    Kikuchi, Toshiaki
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (07) : 3132 - +
  • [37] Combined stereotactic radiosurgery and tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone for the treatment of non-small cell lung cancer patients with brain metastases
    Chiou, Guan-Ying
    Chiang, Chi-Lu
    Yang, Huai-Che
    Shen, Chia-, I
    Wu, Hsiu-Mei
    Chen, Yu-Wei
    Chen, Ching-Jen
    Luo, Yung -Hung
    Hu, Yong-Sin
    Lin, Chung-Jung
    Chung, Wen-Yuh
    Shiau, Cheng-Ying
    Guo, Wan-Yuo
    Pan, David Hung-Chi
    Lee, Cheng-Chia
    JOURNAL OF NEUROSURGERY, 2022, 137 (02) : 563 - 570
  • [38] Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
    Rath, Barbara
    Plangger, Adelina
    Hamilton, Gerhard
    CANCER DRUG RESISTANCE, 2020, 3 (02) : 171 - 178
  • [39] Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer
    Nakanishi, Yu
    Masuda, Takeshi
    Yamaguchi, Kakuhiro
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Nakashima, Taku
    Miyamoto, Shintaro
    Tsutani, Yasuhiro
    Iwamoto, Hiroshi
    Okada, Morihito
    Hattori, Noboru
    Fujitaka, Kazunori
    Miyata, Yoshihiro
    Hamada, Hironobu
    RESPIRATORY INVESTIGATION, 2019, 57 (05) : 451 - 459
  • [40] Prognostic impact and predictive biomarkers of immune checkpoint inhibitor-induced interstitial lung disease for non-small cell lung cancer
    Murata, Daiki
    Azuma, Koichi
    Matsuo, Norikazu
    Tokito, Takaaki
    Hoshino, Tomoaki
    ANNALS OF ONCOLOGY, 2023, 34 : S1430 - S1430
12345